Piper Sandler adjusted its stance on Q32 Bio Inc. (NASDAQ: QTTB), downgrading the biotech firm's stock rating from Overweight to Neutral and significantly reducing the price target to $4.00 from the ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development ...

Eleva, a German biopharmaceutical company, and 3PBIOVIAN, a global contract development and manufacturing organization (CDMO) ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Complement 3 Glomerulopathy Market Outlook 2025-2035: The 7 major complement 3 glomerulopathy market reached a value of USD 9.3 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach ...

This study of Louwe et al. 1 importantly uses clinical cohorts and measurements in humans with atherosclerosis to address the harmful or helpful effects of properdin and contributes a very important ...

For children with nephrotic syndrome, there was no difference in time to relapse between two commonly used non-steroid immunosuppressive medications, according to an observational study that emulated ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Analysts at William Blair upped their FY2024 earnings estimates for Apellis Pharmaceuticals in a report issued on Tuesday, January 21st.